Pay in 4 interest-free payments of $7.39 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Two reviewers independently extracted data and assessed quality
Add-on to 1-3 oral anti-hyperglycemic agents (metformin, sulfonylurea, or SGLT-2 inhibitor) SURPASS-4 (NCT03730662) was a 104-week open-label trial (52-week primary endpoint) that randomized 2002 adult patients with type 2 diabetes mellitus with increased cardiovascular risk to subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg once weekly, or insulin glargine 100 units/mL once daily (1:1:1:3 ratio) on a background of metformin (95%) and/or sulfonylureas (54%) and/or SGLT2 inhibitors (25%)
2008 Dec;138(12):2356-62
Every cell in your body creates waste and gets dirty from things like pollution, stress, and just normal daily life
Consequently, the preliminary findings indicate that the estimated dietary changes may be insufficient to achieve significant short-term reductions in GHGEs
it is a constant, three-phase process that happens every second of the day
US$ 25.46
US$ 20.37
US$ 28.33
US$ 28.98
US$ 29.62
US$ 23.68
US$ 28.99
US$ 20.60
US$ 21.77
